CAPAC

Shasqi Appoints Travis Biechele, Ph.D. as VP of Research to Lead Pipeline Development

Retrieved on: 
Monday, March 11, 2024
Pharmacology, Therapeutic index, Seagen, SAN, Patient, University, Spacecraft, MD, Neoplasm, CAPAC, ADC, Shasqi, Click chemistry, Pharmaceutical industry

SAN FRANCISCO, March 11, 2024 /PRNewswire/ -- Shasqi, Inc. ("Shasqi") a biotech company whose mission is to make cancer drugs more effective with click chemistry, today announced that it has appointed Travis Biechele, Ph.D. as VP of Research.

Key Points: 
  • SAN FRANCISCO, March 11, 2024 /PRNewswire/ -- Shasqi, Inc. ("Shasqi") a biotech company whose mission is to make cancer drugs more effective with click chemistry, today announced that it has appointed Travis Biechele, Ph.D. as VP of Research.
  • Biechele has over two decades of experience in oncology research, with a focus on developing antibody-drug conjugates (ADCs), with both Seagen (now Pfizer) and Merck.
  • Shasqi's pipeline is composed of a range of tumor-targeted activators against validated antigen targets that are combined with protodrugs based on a range of validated payloads.
  • Prior to Merck, Biechele spent 10 years at Seagen (now Pfizer), where he played a pivotal role in the development of ADC technology.

Shasqi to Expand Existing Research Collaboration to Advance Targeted Cancer Treatment

Retrieved on: 
Wednesday, October 4, 2023
Human, Toxicity, Research, Doctor of Philosophy, Nobel Prize in Chemistry, Chemistry, Click chemistry, Cancer, MD, SAN, CAPAC, Biology, Neoplasm, Pharmaceutical industry, Shasqi

Through the collaboration, Shasqi will apply its clinically validated Click Activated Protodrugs Against Cancer (CAPAC®) technology to the development of new cancer therapies.

Key Points: 
  • Through the collaboration, Shasqi will apply its clinically validated Click Activated Protodrugs Against Cancer (CAPAC®) technology to the development of new cancer therapies.
  • The collaboration will expand research on Shasqi's intratumorally injected biopolymer (SQL70), allowing for an additional payload to be developed and advanced through preclinical testing.
  • Using CAPAC, Shasqi is targeting high doses of cancer drugs directly to the site of the tumor, while minimizing toxicity to healthy cells.
  • "Expansion of this collaboration is a testament to the collaborative, productive relationship we have built together."

Shasqi Scientific Advisor Carolyn Bertozzi Awarded Nobel Prize for the Development of Click Chemistry

Retrieved on: 
Thursday, October 6, 2022
University of Copenhagen, SAN, CA, Therapy, Medicine, Click chemistry, Neoplasm, Scripps Research, Animal, Nobel Prize, CAPAC, Patient, Drug development, Biology, Doxorubicin, Research, Cell, Multimedia, Cancer, University, DRS, Nobel Prize in Chemistry, CEO, Paganini Competition, Human, View, Medical imaging, Pharmaceutical industry, Chemistry

SAN FRANCISCO, Oct. 6, 2022 /PRNewswire/ -- Shasqi, a clinical stage biotech company developing oncology therapeutics with its proprietary Click Activated Protodrugs Against Cancer (CAPAC ®) platform, announced today that the company's scientific advisor, Carolyn Bertozzi, Ph.D., has been awarded the 2022 Nobel Prize in Chemistry, alongside Morten Meldal, Ph.D. (University of Copenhagen, Denmark), and Nobel Laureate K. Barry Sharpless, Ph.D. (Scripps Research, La Jolla, CA, USA), for the development of click chemistry and bioorthogonal chemistry.

Key Points: 
  • Dr. Bertozzi and her team demonstrated that these types of reactions could be conducted in cells or animals without interfering with native biochemical processes.
  • "We, at Shasqi, are ecstatic to see that the concept and potential of click chemistry has been recognized by the world's most respected award of scientific achievement, the Nobel Prize.
  • The company's lead asset, SQ3370, has established click chemistry in humans and uses a powerful chemotherapeutic, doxorubicin, as the payload.
  • The lead asset, SQ3370 has established click chemistry in humans and uses a powerful chemotherapeutic, doxorubicin, as the payload.

Shasqi to Present Updated Clinical Data on SQ3370 at the 2022 ASCO Annual Meeting

Retrieved on: 
Tuesday, May 31, 2022
Oncology, Health, Clinical Trials, Research, Science, Biotechnology, Doxorubicin, Constipation, Nausea, Annual general meeting, Patient, Society, American Society of Clinical Oncology, Trial of the century, Cancer, Toxicity, Human, Anemia, Neoplasm, Safety, ASCO, Therapy, CAPAC, McCormick Place, Fatigue, Medical imaging, Medical device, Pharmaceutical industry

Shasqi, a clinical-stage biotechnology company developing precision activated oncology therapeutics with its proprietary Click Activated Protodrugs Against Cancer (CAPAC) platform, will present interim data from its Phase 1 clinical study of SQ3370 in advanced solid tumors, at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting , being held at McCormick Place in Chicago, IL, on June 3-7, 2022.

Key Points: 
  • Shasqi, a clinical-stage biotechnology company developing precision activated oncology therapeutics with its proprietary Click Activated Protodrugs Against Cancer (CAPAC) platform, will present interim data from its Phase 1 clinical study of SQ3370 in advanced solid tumors, at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting , being held at McCormick Place in Chicago, IL, on June 3-7, 2022.
  • It utilizes Shasqis proprietary CAPAC platform, an approach that activates cancer drugs at a tumor with decreased systemic toxicity.
  • Shasqi is validating its platform with SQ3370, which is designed to activate a powerful chemotherapeutic, doxorubicin, at the tumor site.
  • Shasqi is a privately held, clinical-stage biotechnology company whose mission is to enable patients to beat cancer with tumor-localized therapies.

Shasqi Appoints Steve Abella, M.D., as Chief Medical Officer and Scott Wieland, Ph.D., MBA, as SVP of Clinical Development

Retrieved on: 
Tuesday, May 24, 2022
Oncology, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Doxorubicin, Senior, MBA, Webster University, University, UC, Pharmacology, Toxicology, Leadership, Scott, Patient, Therapy, Nanobiotix, Universidad Central del Este, Physiological psychology, Huntsman Cancer Institute, Drug, Wayne State University School of Medicine, Haematopoietic system, Human, University of California, Santa Barbara, Program, Toxicity, Neoplasm, Technology, Leukemia, Safety, Wayne, Drug development, Conjugation, Amgen, Cancer, CAPAC, Drug discovery, Pediatric Oncology Group, Nanomedicine, CA, CEO, University School, Gilead Sciences, Management, Pharmaceutical industry, Medical imaging, Medicine, Neuropharmacology

Shasqi, a clinical-stage biotechnology company developing click chemistry-activated oncology therapeutics, today announced the additions of Steve Abella, M.D., as Chief Medical Officer and Scott Wieland, Ph.D., MBA, as Senior Vice President of Clinical Development.

Key Points: 
  • Shasqi, a clinical-stage biotechnology company developing click chemistry-activated oncology therapeutics, today announced the additions of Steve Abella, M.D., as Chief Medical Officer and Scott Wieland, Ph.D., MBA, as Senior Vice President of Clinical Development.
  • Now is the perfect time to add the deep expertise in clinical strategy and execution that both Steve and Scott bring to the team.
  • Before joining Shasqi, he served as Chief Medical Officer at Vida Development Sciences.
  • Prior to Vida, Steve served as Chief Medical Officer at BioClin Therapeutics.

FISCALNOTE TO HOST MISS AMERICA 2022 FOR AN EVENING CELEBRATION OF ASIAN AMERICAN AND PACIFIC ISLANDER HERITAGE MONTH

Retrieved on: 
Tuesday, May 10, 2022
Congressional Asian Pacific American Caucus, FiscalNote, CAPAC, Culture, CSO, Policy, Capitol Hill, CQ, Association, Organization, Truth or Dare: 6th Floor Rear Flat, History, Asian Americans, Congress, Korean Americans, Software as a service, CEO, Transport, Guest, Risk, Airline, Labour, Miss America, American

WASHINGTON, May 10, 2022 /PRNewswire/ -- FiscalNote, a leading AI-driven enterprise SaaS company that delivers legal and regulatory data and insights, today announced Miss America 2022, Emma Broyles of Anchorage, Alaska, will be the Guest of Honor at FiscalNote's Washington, D.C. headquarters on Thursday, May 12th at 6 p.m. for an evening to celebrate May as Asian American and Pacific Islander Heritage Month, joined by the Congressional Korean American Staff Association (CKASA) and hosted by FiscalNote.

Key Points: 
  • Congressional Korean American Staff Association of Capitol Hill to Join Emma Broyles, the first Korean-American Miss America, at Washington, D.C.
  • Miss Broyles made history as the first Korean-American to be named Miss America in the pageant's 100 year history.
  • FiscalNote is located at 1201 Pennsylvania Ave., 6th Floor, in downtown Washington, D.C.
    For more information about Miss America, Emma Broyles, please visit: https://www.missamerica.org/emma-broyles/ .
  • To learn more about FiscalNote and its family of brands, visit FiscalNote.com and follow @FiscalNote.

Shasqi to Present on SQ3370 and CAPAC™ Platform Expansion at the American Association for Cancer Research (AACR) 2022 Annual Meeting

Retrieved on: 
Thursday, March 17, 2022
Oncology, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, CAPAC, Plasma, Human, Therapy, Trial of the century, AACR, American Association, Neoplasm, Cancer, Doxorubicin, CEO, Association, Safety, American Association for Cancer Research, Patient, MMAE, Toxicity, Pharmaceutical industry, Medical imaging, CAPAC and SQ3370, Shasqi, CAPAC AND SQ3370, SHASQI

Weve also demonstrated that our click chemistry platform can activate high doses of MMAE, a commonly used antibody-drug conjugate payload, at the tumor.

Key Points: 
  • Weve also demonstrated that our click chemistry platform can activate high doses of MMAE, a commonly used antibody-drug conjugate payload, at the tumor.
  • It utilizes Shasqis proprietary CAPAC platform, an approach that activates cancer drugs at a tumor with decreased systemic toxicity.
  • Shasqi is validating its platform with SQ3370, which is designed to activate a powerful chemotherapeutic, doxorubicin, at the tumor site.
  • Shasqi is a privately held, clinical-stage biotechnology company whose mission is to enable patients to beat cancer with tumor-localized therapies.

Shasqi to Present at the 40th Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Friday, January 7, 2022
Research, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Oncology, Toxicity, Safety, Founder, Therapy, Patient, Cancer, Conference, EST, CEO, Doxorubicin, Neoplasm, Human, CAPAC, Pharmaceutical industry, Oneto, CAPAC and SQ3370, Shasqi, CAPAC AND SQ3370, SHASQI

Shasqi, a clinical-stage biotechnology company developing precision activated oncology therapeutics with its proprietary Click Activated Protodrugs Against Cancer (CAPAC) Platform, announced today that its Founder and CEO, Jos M. Meja Oneto, M.D., Ph.D., will present at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022, at 10 a.m. EST.

Key Points: 
  • Shasqi, a clinical-stage biotechnology company developing precision activated oncology therapeutics with its proprietary Click Activated Protodrugs Against Cancer (CAPAC) Platform, announced today that its Founder and CEO, Jos M. Meja Oneto, M.D., Ph.D., will present at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022, at 10 a.m. EST.
  • The presentation will be available as a live webcast through the J.P. Morgan Healthcare Conference portal and an archived recording will be made available after the event.
  • Shasqi is validating its platform with SQ3370, which is designed to activate a powerful chemotherapeutic, doxorubicin, at the site of the tumor.
  • Shasqi is a privately held, clinical-stage biotechnology company whose mission is to enable patients to beat cancer with tumor-localized therapies.

Shasqi Awarded a Second NCI Grant of $1.9M to Accelerate the Development of SQ3370

Retrieved on: 
Wednesday, December 8, 2021
Science, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, Clinical Trials, Human, Neoplasm, Toxicity, National Cancer Institute, Therapy, Safety, SBIR, Patient, CEO, Cancer, National, NCI, Doxorubicin, CAPAC, Investment, Pharmaceutical industry, CAPAC and SQ3370, Shasqi, CAPAC AND SQ3370, SHASQI

The $1.9 million grant will support a Phase 1b dose-expansion cohort in the companys ongoing development program for its click-activated prodrug therapy, SQ3370.

Key Points: 
  • The $1.9 million grant will support a Phase 1b dose-expansion cohort in the companys ongoing development program for its click-activated prodrug therapy, SQ3370.
  • "The NCI has made two investments in our Phase 1 clinical studies of SQ3370, which will enable us to accelerate the development of SQ3370 and gather additional efficacy and safety data to inform our Phase 2 clinical trial design.
  • We are grateful for the vision of the NCI and their support of SQ3370 and our click chemistry platform," said Jos M. Meja Oneto, M.D., Ph.D., Founder and CEO of Shasqi.
  • Shasqi is validating its platform with SQ3370, which is designed to activate a powerful chemotherapeutic, doxorubicin, at the site of the tumor.

Shasqi Raises $50 Million to Expand Click Chemistry Platform Beyond Injectable Tumors and Accelerate Lead Clinical Program

Retrieved on: 
Thursday, November 11, 2021
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Safety, SITC, Click chemistry, Industry, Society for Immunotherapy of Cancer, European Society for Medical Oncology, Radiopharmaceutical, Neoplasm, CEO, Congress, Technology, Trial of the century, Society, ESMO, Injection, Human, Board, Interim, Partnership, Therapy, Doxorubicin, Toxicity, Oncology, Immunotherapy, CAPAC, Patient, Pharmaceutical industry, Vaccine

The funds will be used to advance the Phase 1/2 clinical study of SQ3370 for the treatment of injectable, advanced solid tumors, and will enable Shasqi to expand its click chemistry platform to create therapeutics that do not require intratumoral injections.

Key Points: 
  • The funds will be used to advance the Phase 1/2 clinical study of SQ3370 for the treatment of injectable, advanced solid tumors, and will enable Shasqi to expand its click chemistry platform to create therapeutics that do not require intratumoral injections.
  • Data from our lead program shows us that click chemistry works in humans and the early validation gives us even greater confidence in our approach.
  • We expect this expansion to open up the path for the platform to antibody-based approaches, immune cell engagers, radiopharmaceuticals and more.
  • Mr. Rieflin commented, The Shasqi team has parlayed $18 million into an ongoing Phase 1/2 clinical study of SQ3370 and a click chemistry platform that is poised for expansion into antibody-based and other targeted modalities.